Clinical trialNCT06919003RecruitingPhase 2Interventional

Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment180Kidney Transplant

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to find out if Berinert can improve kidney function in the first year after transplant and to find out what effects, good or bad, Berinert will have in the kidney recipient. This research study will compare Berinert to placebo. The placebo looks exactly like Berinert but does not contain any active drug. Placebos are used in research studies to see if the results are due to the study drug or due to other reasons. Neither you or the study doctor can choose or know which group is assigned. The primary objective is to test whether intrarenal artery C1 esterase inhibitor (C1INH) injection into the donor kidney prior to transplantation improves kidney function in recipients of high risk, deceased donor kidney transplants as measured by 12-month Estimated Glomerular Filtration Rate (eGFR) Chronic Kidney Disease Epidemiology Collaboration (CDK-EPI)

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Peter S Heeger, MD
Cedars-Sinai Medical Center
Study Chair
clinicaltrials.gov ↗
Sindhu Chandran, MBBS, MD
Cedars-Sinai Medical Center
Study Chair
clinicaltrials.gov ↗
Stanley Jordan, MD
Cedars-Sinai Medical Center
Study ChairKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Cedars Sinai Medical Center
Los Angeles, California, United States
Recruiting
Northwestern Memorial Hospital
Chicago, Illinois, United States
Recruiting
Kansas University Medical Center
Kansas City, Kansas, United States
Recruiting
Montefiore Medical Center
The Bronx, New York, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

C1 esterase inhibitor →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 22 Sept 2025
Primary completion: 30 May 2031
Completion: 30 May 2032
Last update posted: 27 Feb 2026
Registered enrollment: 180
Registry id: NCT06919003

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.